Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Multi-Omics Analysis of Proteasome Inhibitor Resistance in Multiple Myeloma

Seungbin Han, Chien-Yun Lee, Lenka Besse, Umair Munawar, Andrej Besse, Ann-Sohpie Hainold, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Xiang Zhou, Larissa Haertle, Johannes Waldschmidt, Christoph Driessen, Hermann Einsele, Leo Rasche, Bernhard Kuster, K. Martin Kortüm

Blood (2024) 144 (Supplement 1): 6817.

https://doi.org/10.1182/blood-2024-203352

Published: 2024

Journal Articles

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Guldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyun Kim, Dominik Dytfeld, Jiří Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vassalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk

Blood (2024) 144 (Supplement 1): 494.

https://doi.org/10.1182/blood-2024-205608

Published: 2024

Journal Articles

Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Blood (2024) 144 (Supplement 1): 487.

https://doi.org/10.1182/blood-2024-199550

Published: 2024

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Blood (2024) 144 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2024-201630

Published: 2024

Journal Articles

Regulation of BCMA By the Ubiquitin Proteasome System Enables Optimization of BCMA-Targeting Therapies in Multiple Myeloma

Leonie Rieger, Kilian Irlinger, Franziska Fuechsl, Nicolas Barbian, Marlene Tietje, Melanie Faber, Tobias Schulze, Piero Giansanti, Lenka Besse, Christoph Driessen, Angela Krackhardt, Bernhard Kuster, Florian Bassermann

Blood (2023) 142 (Supplement 1): 3310.

https://doi.org/10.1182/blood-2023-187349

Published: 2023

Journal Articles

A National Platform and Scoring System Allocates CAR-T Treatment Slots for Multiple Myeloma to Patients with High Likelihood of Complete Remission

Christoph Driessen, Katharina Baur, Dominik Heim, Sabine Gerull, Christoph Renner, Anne Cairoli, Thomas Pabst, Joerg Halter, Michael Gregor, Nicole Graf, Nino Fejzibegovic, Nathan Wolfensberger, Federico Simonetta, Martin Fehr, Esteban Ciliberti, Rouven Müller, Barbara Jeker

Blood (2023) 142 (Supplement 1): 4701.

https://doi.org/10.1182/blood-2023-182628

Published: 2023

Journal Articles

Targeting IGF1R/Insr Pathway with Approved ALK-Inhibitors Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma

Max Alberto Mendez-Lopez, Andrej Besse, Tiberiu Totu, Marianne Kraus, Anthonius P.A. Janssen, Marija Buljan, Mario Van Der Stelt, Lenka Besse, Christoph Driessen

Blood (2023) 142 (Supplement 1): 4663.

https://doi.org/10.1182/blood-2023-177912

Published: 2023

Journal Articles

Impact of ABCB1 Promoter Methylation on PI-Resistance in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12462–12463.

https://doi.org/10.1182/blood-2022-168694

Published: 2022

Journal Articles

MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7289–7291.

https://doi.org/10.1182/blood-2022-159756

Published: 2022

Journal Articles

Bortezomib Resistant Multiple Myeloma Shows a Specific Dependency on Ecpas in Vitro and In Vivo

Lenka Besse, Andrej Besse, Sara C. Stolze, Amin Sobh, Marianne Kraus, Hirofumi Nakagami, Christoph Driessen

Blood (2022) 140 (Supplement 1): 4183–4184.

https://doi.org/10.1182/blood-2022-167648

Published: 2022

Journal Articles

The Molecular Landscape and Essential Pathways Involved in Bone Marrow-Mediated Carfilzomib Resistance of Multiple Myeloma

Jonas Schwestermann, Andrej Besse, Serena Fazio, Cesar Nombela-Arrieta, Lenka Besse, Christoph Driessen

Blood (2022) 140 (Supplement 1): 4228–4229.

https://doi.org/10.1182/blood-2022-169024

Published: 2022

Journal Articles

Blocking the Don't Eat Me Signal (CD47-SIRPα Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma

Katja Klausz, Carina Lynn Gehlert, Ammelie Svea Boje, Marta Lustig, Steffen Krohn, Syeda Maliha Ahmed, Christian Kellner, Thomas Valerius, Lenka Besse, Andrej Besse, Christoph Driessen, Martin Gramatzki, Matthias Peipp

Blood (2021) 138 (Supplement 1): 2684.

https://doi.org/10.1182/blood-2021-152208

Published: 2021

Journal Articles

High-Dose Carfilzomib Recaptures Response in Relapsed/Refractory Multiple Myeloma Resistant to Low-Dose Carfilzomib By Co-Inhibiting β2 Subunit of Proteasome Complex: The First in Human Evidence

Xiang Zhou, Andrej Besse, Jessica Peter, Max Mendez Lopez, Larissa Haertle, Umair Munawar, Seungbin Han, Elmer Maurits, Herman S. Overkleeft, Hermann Einsele, Christoph Driessen, Martin Kortuem, Lenka Besse, Leo Rasche

Blood (2021) 138 (Supplement 1): 818.

https://doi.org/10.1182/blood-2021-147170

Published: 2021

Journal Articles

Essential Drug Targets and Pathways in PI-Resistant MM Cells

Andrej Besse, Lenka Besse, Lorina Büchler, Sara C. Stolze, Amin Sobh, Marianne Kraus, Hirofumi Nakagami, Christoph Driessen

Blood (2021) 138 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2021-150117

Published: 2021

Journal Articles

The Molecular Landscape and Essential Pathways Involved in Bone Marrow-Mediated Carfilzomib Resistance of Multiple Myeloma

Jonas Schwestermann, Andrej Besse, Lenka Besse, Christoph Driessen

Blood (2021) 138 (Supplement 1): 1571.

https://doi.org/10.1182/blood-2021-148395

Published: 2021

Journal Articles

Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137575

Published: 2020

Journal Articles

All-Trans-Retinoic Acid Prevents Carfilzomib-Induced Cardiotoxicity By Decreasing Activation of the Renin-Angiotensin System

Max A Mendez, Andrej Besse, Bogdan I. Florea, Christian Zuppinger, Herman S. Overkleeft, Lenka Besse, Christoph Driessen, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139277

Published: 2020

Journal Articles

Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95)

Blood (2020) 136 (Supplement 1): 46–48.

https://doi.org/10.1182/blood-2020-139337

Published: 2020

Journal Articles

Effect of ABCB1 Multidrug Resistance Protein on Efficacy of Anti-Myeloma Drugs in Carfilzomib-Resistant Myeloma Model

Konstantin Byrgazov, PhD, Marianne Kraus, Andrej Besse, Ana Slipicevic, Fredrik Lehmann, Christoph Driessen, MD, Lenka Besse

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136725

Published: 2020

Journal Articles

Nelfinavir Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma By Modulating Membrane Lipid Bilayer Composition and Fluidity

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-136253

Published: 2020

NARROW

Multi-Omics Analysis of Proteasome Inhibitor Resistance in Multiple Myeloma

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Regulation of BCMA By the Ubiquitin Proteasome System Enables Optimization of BCMA-Targeting Therapies in Multiple Myeloma

A National Platform and Scoring System Allocates CAR-T Treatment Slots for Multiple Myeloma to Patients with High Likelihood of Complete Remission

Targeting IGF1R/Insr Pathway with Approved ALK-Inhibitors Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma

Impact of ABCB1 Promoter Methylation on PI-Resistance in Multiple Myeloma

MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Bortezomib Resistant Multiple Myeloma Shows a Specific Dependency on Ecpas in Vitro and In Vivo

The Molecular Landscape and Essential Pathways Involved in Bone Marrow-Mediated Carfilzomib Resistance of Multiple Myeloma

Blocking the Don't Eat Me Signal (CD47-SIRPα Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma

High-Dose Carfilzomib Recaptures Response in Relapsed/Refractory Multiple Myeloma Resistant to Low-Dose Carfilzomib By Co-Inhibiting β2 Subunit of Proteasome Complex: The First in Human Evidence

Essential Drug Targets and Pathways in PI-Resistant MM Cells

The Molecular Landscape and Essential Pathways Involved in Bone Marrow-Mediated Carfilzomib Resistance of Multiple Myeloma

Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

All-Trans-Retinoic Acid Prevents Carfilzomib-Induced Cardiotoxicity By Decreasing Activation of the Renin-Angiotensin System

Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95)

Effect of ABCB1 Multidrug Resistance Protein on Efficacy of Anti-Myeloma Drugs in Carfilzomib-Resistant Myeloma Model

Nelfinavir Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma By Modulating Membrane Lipid Bilayer Composition and Fluidity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only